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558a Wednesday, February 6, 2013nanodiscs is accomplished by its addition to the initial lipid and MSP mixture.
Microscale thermophoresis (MST) is a recently developed technology that
studies interactions based on the differential movement of biomolecules and
their complexes in a microscopic temperature gradient. MST is highly sensi-
tive, since it depends on changes in the size, charge and hydration shell of mol-
ecules. It measures interactions in free solution (no coupling required) and
needs only very low sample volumes. It thus provides advantages over existing
techniques like fluorescence correlation spectroscopy (FCS), isothermal titra-
tion calorimetry (ITC) and surface plasmon resonance (SPR). The use of nano-
discs in MST-based interaction studies of membrane proteins with ligands, or
of lipid membranes with soluble peptides is very appealing. We thus explored
this approach experimentally. Potential pitfalls of the method (aggregation of
nanodiscs, undesired interactions with the capillary walls, etc.) were addressed
and ways to overcome such difficulties are presented. Finally, MST was suc-
cessfully applied for the measurement of binding affinities between various
membrane proteins and their ligands.
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Specific protein-protein interactions control many crucial processes of the liv-
ing cell. We aim at elucidating specificity of the interactions at the model sys-
tem of interferon gamma (IFNg) and its cellular receptor 1 (IFNgRec1), the
system important in innate immunity. To modulate (increase as well as de-
crease) specificity of the interaction we searched for mutations of the receptor
molecule that was subjected to in silico mutations using the crystallographi-
cally determined structures of IFNg/IFNgRec1 complex. Amino acid substitu-
tions were modeled by empirical force field implemented in the web-based
software FoldX. About twenty computer-selected candidate mutants of IFN-
gRec1 were successfully expressed in Escherichia coli, purified to homogeneity
and their affinities to IFNg were determined by surface plasmon resonance
(SPR). The SPR measurements showed that affinity of most receptor variants
designed for affinity increase had their affinity virtually unchanged, a few
had affinity slightly lower but a few bound with affinity significantly higher.
Simple and computationally cheap method was therefore able to predict in-
crease of affinity. The receptor variants with increased affinity may be used
for diagnostic purposes.
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Human ClC-5 is a Cl/Hþ antiporter belonging to the CLC family, which in-
cludes both Cl channels and Cl/Hþ antiporters. Small organic molecules
have been useful tools for studying ion channels and many commercial drugs
target specific ion channel proteins. Some blockers have been found to inhibit
the plasma membrane localized CLC channels ClC-0, ClC-1 and ClC-Ka.
However, high-affinity ligands for most CLCs are missing.
Here, we tested the benzofuran derivative RT-931,2 on ClC-5 and ClC-4. Inter-
estingly RT-93 inhibits ClC-5 (EC50 ~ 200 mM), but has only a small effect on
the highly homologous antiporter ClC-4. Towards our goal to identify the bind-
ing site of RT-93 on ClC-5, we constructed 12 chimeras between ClC-4 and
ClC-5. Guided by the crystal structure of a bacterial CLC protein and using
the alignment between ClC-4 and ClC-5, we identified the sequence stretches
with the main differences between these two proteins and substituted in ClC-
5 the portions with the corresponding sequence of ClC-4. We expect to remove
the RT-93 sensitivity at least in one of these. So far we tested 8 chimeras, none
of which, however, showed a significant difference in comparison with ClC-5.
If none of the chimeras eliminates the binding site we will proceed with con-
structing larger chimeras.
Discovering the binding site of this blocker might help in creating a more effi-
cient ligand that, apart from being a useful biophysical tool, may provide a way
to modulate protein function in vivo.
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The origin of many disease states has been linked to genetic mutations, defects
in gene expression, nuclear excision repair and ribosome biogenesis. Centrin,
a calcium binding protein, which has recently been found to regulate some
of these processes along other target proteins within the nucleus. One target,
Krr1, contains a K homology (KH) domain; which has been identified as a nu-
cleic acid recognition motif, required for proper processing of pre-rRNA, for
synthesis of 18S rRNA, and for the assembly of the 40S subunit. Our initial
findings have identified a putative centrin binding site located within the KH
domain of Krr1 using bioinformatics tools. In this study, the KH domain
(192 bp) was amplified by PCR and then ligated to the expression vector
pET100. Colony PCR was performed to identify the E. coli colonies that
have been transformed effectively with the desired recombinant. The Krr1
KH domain fragment was then overexpressed. An isolation and purification
protocol has been designed which includes preparative centrifugation, cross
flow and tangential flow filtration and two ion exchange chromatography.
The evaluation of the purification of the KH domain fragment has been per-
formed by SDS-PAGE and peptide samples have been sent for MS analysis
and partial amino acid sequencing.
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Mesothelin is a cell surface protein that is normally found in mesothelial cells
lining the pleura, pericardium and peritoneum, but is aberrantly expressed at
high level in a variety of cancers including mesothelioma, ovarian, pancreatic
and lung cancers. Although the physiological function of mesothelin is unclear,
studies have shown that it is capable of binding to the tumor antigen CA-125
(also known as MUC16), leading to cell adhesion and tumor metastasis. Since
mesothelin is specifically expressed at a significantly higher level in malignant
tumors, development of an antibody against mesothelin is therefore of major
importance in the field of cancer therapy. MORAb-009 is a humanized mono-
clonal antibody against mesothelin currently under clinical trials. Animal ex-
periments have shown that application of MORAb-009 in combination with
chemotherapy leads to a marked reduction in tumor growth of mesothelin-
expressing tumors.
We show here that MORAb-009 recognizes a non-linear epitope that is con-
tained in the first 64-residue fragment of the mesothelin. We further demon-
strate that the recognition is sensitive to the loss of a disulfide bond linking
residues Cys7 and Cys31. The crystal structure of the complex between the
mesothelin N-terminal fragment and Fab of MORAb-009 at 2.6 A˚ resolution
reveals an epitope encompassing multiple secondary structural elements of
the mesothelin, The mesothelin fragment has a compact, right-handed superhe-
lix structure consisting of five short helices and connecting loops. A residue es-
sential for complex formation has been identified as Phe22, which projects its
side chain into a hydrophobic niche formed on the antibody’s recognition sur-
face upon antigen-antibody contact. The overlapping binding footprints of both
the monoclonal antibody and the cancer antigen CA125 explains the therapeu-
tic effect and provides a basis for further antibody improvement.
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A series of [(2-pyrimidinylthio)acetyl]benzenesulfonamides were designed
and synthesized. their binding affinities as inhibitors of several recombinant
human carbonic anhydrase (CA) isozymes were determined by isothermal
titration calorimetry and thermal shift assay yielding intrinsic Gibbs free en-
ergies, enthalpies, entropies, and heat capacities of binding. A group of com-
pounds containing a chlorine atom in the benzenesulfonamide ring were found
to exhibit higher selectivity but lower binding affinity toward tested CAs. The
crystal structures of selected compounds in complex with several CAs were
determined and the docking studies were performed to compare the binding
